From The Editor | November 19, 2026

When Sponsors Say "Fair Market Value," Do They Know Where It Comes From?

John Oncea Profile Photo

By John Oncea, Chief Editor, Clinical Tech Leader

increasing value, business product, service-GettyImages-1344940351

Rod Butt has heard the phrase “company policy” more times than he can count, and by now he knows what it usually means: nobody on the other end of the call can actually explain where a number came from.

Butt recently retired from a 30-year career that included stops at SmithKline & French, GSK, and Boehringer Ingelheim, most recently as director of clinical research and drug development. Since retiring from that side of the industry, he has spent his time on the opposite end of the table, working directly with investigator sites, many of them physicians who never trained to negotiate a pharma contract.

That switch in vantage point is what makes his current observation interesting. It is not that sponsors are dishonest; it’s that a lot of the technology and terminology built into modern trial contracting, from electronic signature platforms to “fair market value” budget benchmarks, gets applied by people who cannot show their work.

A $12,000 Signature For A $1,000 Problem

One of Butt’s recurring arguments with sponsors involves 21 CFR Part 11, the FDA regulation governing electronic records and signatures used in clinical trial data submitted as part of a drug application. Sponsors will insist that every electronic system touching the trial, including the clinical trial agreement itself, has to run on Part 11-validated infrastructure.

Butt pushes back on that every time. “A doctor’s agreement with the sponsor is not clinical trial data,” he said. “Therefore, it does not have to be Part 11 compliant. You have to have a verified system, but it does not have to be a validated Part 11 compliance system.”

He points to DocuSign as the clearest example. A basic verified e-signature setup runs roughly $1,000. The Part 11 validated version runs roughly $12,000. When a sponsor insists the contract has to be signed on the validated platform, Butt’s response is direct: “I’m sure you’re familiar with things like DocuSign. You can get the DocuSign Part 11 compliant version for $12,000, or you could get the verified system for $1,000.” He says he has correspondence from the FDA backing his reading of the rule. The only systems that require Part 11 validation, he said, are ones that touch clinical trial data as part of an NDA submission. A signed agreement between a sponsor and a physician is not that.

Even armed with that distinction, Butt said the conversation rarely resolves on logic. “I say, ‘Show me why.’ And of course, they can’t do that because it’s not there. It doesn’t exist. And they always revert back at the end of the day saying, ‘Oh, it’s a company policy.’”

The Same Problem Shows Up In Budgets

The Part 11 argument is a smaller version of a much bigger one Butt runs into constantly: sponsors and CROs citing “fair market value” as the ceiling on what a site can be paid, without being able to explain how that value was calculated.

“They throw out these things like fair market value, et cetera,” Butt said. “And when you push back, it’s very clear that the contract person associated with that sponsor doesn’t fully understand where the numbers come from.”

Rather than accept an unsupported number, Butt built his own fair market value model, anchored to a methodology already used and defended in a regulatory context: the Canada Revenue Agency’s Scientific Research and Experimental Development (SR&ED) program, which calculates fully loaded costs for tax credit purposes. When a sponsor cites a figure he considers arbitrary, he brings his own model to the table instead. “Here’s our FMV model,” he tells them. “Our fair market value model is based on Revenue Canada.”

He described a live example from the week of the interview: a sponsor claiming a “high FMV” for a line item, with no supporting calculation offered. Butt’s response was to hand over his own cost table and billing rate, built around figures aligned with what a CRO would actually charge for the same work.

Why The Gap Persists

Part of the problem, in Butt’s view, is structural. Many sponsors now negotiate through CROs or functional service providers rather than directly, and those intermediaries are often boxed in by their own contract parameters. “The CRO obviously is looking at their parameters is based on their contract with the sponsor,” he said. “They might have timelines. They might have budget numbers they have to work with.”

When Butt’s model produces a number outside what a CRO representative has been authorized to approve, the answer is often that it falls “outside of our parameters,” even when the representative privately agrees the number is reasonable. His advice in that situation is simple: take it back to the sponsor because the sponsor is the final decision-maker.

He is also skeptical of leaning too hard on AI-driven budgeting tools now built into some clinical trial management systems, not because the tools are inherently bad, but because they inherit the same problem. “We cannot rely on the AI tools that are emerging right now that sometimes are built into the various systems,” he said, “because they may or may not accurately reflect what’s going on a fundamental basis.” An algorithm trained on incomplete assumptions about cost still produces a number nobody can defend, just faster.

The Practical Fix

Butt’s approach is not adversarial for its own sake; it’s a demand for the same transparency any other vendor negotiation would require: show the inputs, not just the output. For sites without someone playing that role, the alternative is accepting benchmark figures that may have no real calculation behind them at all, whether the topic is a signature platform, a per-visit rate, or a line labeled simply “FMV.”

For sponsors, the lesson cuts the other way. A contracting team that can show its work, rather than falling back on “company policy,” spends less time in exactly the kind of standoff Butt described, and builds more credibility with the sites it needs to keep recruiting for the next study.